Literature DB >> 29869121

Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer.

Hou-Hsuan Cheng1,2, Jen-Kou Lin1,3, Wei-Shone Chen1,3, Jeng-Kai Jiang1,3, Shung-Haur Yang4,5, Shih-Ching Chang6,7,8.   

Abstract

BACKGROUND: To investigate the clinicopathological features and prognostic significance of the BRAFV600E mutation in Asian patients with colorectal cancer.
METHODS: We retrospectively reviewed the medical records of 1969 patients with colorectal cancer admitted to Taipei Veterans General Hospital for surgical treatment between 2000 and 2013. The measured endpoint was overall survival after surgery. The prognostic value of the BRAFV600E mutation was analyzed using the log-rank test and Cox regression analysis.
RESULTS: The BRAFV600E mutation was detected in 106 (5.4%) patients and associated with female gender, abnormal cancer antigen (CA)19-9 at diagnosis, microsatellite status, right-sided primary tumors, mucinous histology, poor differentiation, and lymphovascular invasion. Metastatic patterns were more common in non-regional lymph node metastasis (20.8 vs. 7.4%, p = 0.06) and peritoneal seeding (41. vs. 21.2%, p = 0.04). Mutations were not prognostic in the overall survival of the entire study group but only in specific patients: age < 65, normal carcinoembryonic antigen at diagnosis, and stage IV disease.
CONCLUSION: The BRAFV600E mutation was associated with distinct clinicopathological features and metastatic patterns. The overall survival rate was lower in selected colorectal patients with the BRAFV600E mutation.

Entities:  

Keywords:  BRAF mutation; Colorectal cancer; Metastatic pattern; Stage IV; Survival

Mesh:

Substances:

Year:  2018        PMID: 29869121     DOI: 10.1007/s00384-018-3095-6

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  49 in total

1.  Variations in Metastasis Site by Primary Location in Colon Cancer.

Authors:  Ramzi Amri; Liliana G Bordeianou; Patricia Sylla; David L Berger
Journal:  J Gastrointest Surg       Date:  2015-05-02       Impact factor: 3.452

2.  Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.

Authors:  Timothy J Price; Jennifer E Hardingham; Chee K Lee; Andrew Weickhardt; Amanda R Townsend; Joseph W Wrin; Ann Chua; Aravind Shivasami; Michelle M Cummins; Carmel Murone; Niall C Tebbutt
Journal:  J Clin Oncol       Date:  2011-06-06       Impact factor: 44.544

3.  BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.

Authors:  Christopher W Toon; Michael D Walsh; Angela Chou; David Capper; Adele Clarkson; Loretta Sioson; Stephen Clarke; Scott Mead; Rhiannon J Walters; Mark Clendenning; Christophe Rosty; Joanne P Young; Aung Ko Win; John L Hopper; Ashley Crook; Andreas von Deimling; Mark A Jenkins; Daniel D Buchanan; Anthony J Gill
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

4.  KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.

Authors:  Hong-Tao Li; Yuan-Yuan Lu; Yan-Xin An; Xin Wang; Qing-Chuan Zhao
Journal:  Oncol Rep       Date:  2011-03-17       Impact factor: 3.906

5.  BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.

Authors:  Matthew F Kalady; Kathryn L Dejulius; Julian A Sanchez; Awad Jarrar; Xiuli Liu; Elena Manilich; Marek Skacel; James M Church
Journal:  Dis Colon Rectum       Date:  2012-02       Impact factor: 4.585

6.  Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.

Authors:  Michael J O'Brien; Shi Yang; Charline Mack; Huihong Xu; Christopher S Huang; Elizabeth Mulcahy; Mark Amorosino; Francis A Farraye
Journal:  Am J Surg Pathol       Date:  2006-12       Impact factor: 6.394

7.  Microbiota organization is a distinct feature of proximal colorectal cancers.

Authors:  Christine M Dejea; Elizabeth C Wick; Elizabeth M Hechenbleikner; James R White; Jessica L Mark Welch; Blair J Rossetti; Scott N Peterson; Erik C Snesrud; Gary G Borisy; Mark Lazarev; Ellen Stein; Jamuna Vadivelu; April C Roslani; Ausuma A Malik; Jane W Wanyiri; Khean L Goh; Iyadorai Thevambiga; Kai Fu; Fengyi Wan; Nicolas Llosa; Franck Housseau; Katharine Romans; XinQun Wu; Florencia M McAllister; Shaoguang Wu; Bert Vogelstein; Kenneth W Kinzler; Drew M Pardoll; Cynthia L Sears
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

8.  Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival.

Authors:  Frank Benedix; Rainer Kube; Frank Meyer; Uwe Schmidt; Ingo Gastinger; Hans Lippert
Journal:  Dis Colon Rectum       Date:  2010-01       Impact factor: 4.585

9.  Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.

Authors:  D P Modest; I Ricard; V Heinemann; S Hegewisch-Becker; W Schmiegel; R Porschen; S Stintzing; U Graeven; D Arnold; L F von Weikersthal; C Giessen-Jung; A Stahler; H J Schmoll; A Jung; T Kirchner; A Tannapfel; A Reinacher-Schick
Journal:  Ann Oncol       Date:  2016-06-29       Impact factor: 32.976

10.  Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.

Authors:  R Dienstmann; M J Mason; F A Sinicrope; A I Phipps; S Tejpar; A Nesbakken; S A Danielsen; A Sveen; D D Buchanan; M Clendenning; C Rosty; B Bot; S R Alberts; J Milburn Jessup; R A Lothe; M Delorenzi; P A Newcomb; D Sargent; J Guinney
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

View more
  2 in total

1.  Risk Factors for Synchronous Peritoneal Metastases in Colorectal Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yuanxin Zhang; Xiusen Qin; Rui Luo; Hui Wang; Huaiming Wang; Hongzhi Luo
Journal:  Front Oncol       Date:  2022-06-20       Impact factor: 5.738

Review 2.  Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer.

Authors:  Mengdi Hao; Kun Wang; Yuhan Ding; Huimin Li; Yin Liu; Lei Ding
Journal:  Eur J Med Res       Date:  2022-07-25       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.